{"analyses":[{"ciLowerLimit":"16.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"42.18","estimateComment":"The Estimate Value is a percentage.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"The Confidence Interval are percentages.","pValue":"<0.001","paramType":"Risk Difference (RD)","paramValue":"29.55","statisticalMethod":"Mantel Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL1/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).","groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"OG000","title":"Asciminib (Imatinib Stratum)"},{"description":"Patients took on ongoing basis the Investigator selected TKI (imatinib)","id":"OG001","title":"Investigator Selected TKI (Imatinib Stratum)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The IMA Full Analysis Set (FASIMA) comprised of all participants from the FAS, whose PRS TKI is imatinib. FAS comprised of all participants to whom study treatment has been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"At 48 weeks","title":"Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)","type":"PRIMARY","unitOfMeasure":"Participants"}